Content

Welcome Message ........................................................................4
General Information ........................................................................5
Chairs and Faculty ........................................................................9
Scientific Programme .....................................................................13
Faculty Disclosure .........................................................................19
Faculty Biographies .......................................................................22
Educational Objectives .............................................................. 35
Funding ........................................................................................53
Dear Colleagues,

It is a great pleasure to welcome you to the Quality Standards and Innovation in Assisted Reproductive Technologies International Conference.

This medical education activity, will provide a unique opportunity for researchers and medical practitioners to become better acquainted with this expanding area and to take the opportunity to interact and share experiences with colleagues.

Our eminent faculty will guide you on a journey of evidence from basic science to clinical practice. As your hosts, we would like to thank you for joining us here in Moscow and hope that you will find this educational programme scientifically stimulating, highly engaging, and enjoyable.

With kind regards,

Carlo Alviggi
University Federico II
Naples, Italy

Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Robert Fischer
Fertility Center Hamburg
Hamburg, Germany

Peter Humaidan
Fertility Clinic, Skive Regional Hospital Faculty of Health, Aarhus University
Aarhus, Denmark
General Information
Conference Overview

This conference will focus on how controlled ovarian stimulation (COS) plays a major role in optimising IVF patient outcomes. We will discuss how to achieve maximal success with minimal side effects, how the regulation of COS can boost the number of oocytes available, new advances in ovarian stimulation strategies, and the latest knowledge of ovarian physiology. Understanding developments in COS will provide healthcare professionals with the knowledge to achieve the optimal outcome for patients.

Assisted reproductive technology (ART) depends on carefully controlled conditions at every stage of the procedure to be successful. Continuous advances in technology require constant revision of good laboratory practices and the introduction of new techniques. Conference attendees will leave with an understanding of the latest technologies, and laboratory practice guidelines.

This conference offers an interactive programme with specialised lectures tailored to fit the needs of physicians and embryologists working in ART. There will be opportunity to discuss directly with renowned scientists pertinent topics that have been the subject of controversy and innovation. Discussions will focus on how to achieve optimal laboratory conditions, culture environments, selection criteria, and how to select the best therapy for infertile patients. Discussions will help give clarity to latest research and approaches to ART.
Learning Objectives

After attending the conference, attendees will be able to:

• Identify the key factors influencing the success of ART
• Assess successful outcome of ART using laboratory and clinical outcomes
• Create an optimal stimulation protocol tailored for patients undergoing ART
• Discuss and debate evolving approaches to ART

Target Audience

This programme is designed for clinicians and biologists working in assisted reproductive medicine, who want to acquire up-to-date information for improving their current practice.

Language

The official language of this live educational conference will be English. Simultaneous translation from English to Russian and vice versa will be provided.
Accreditation

MedE.A. (www.medea.academy) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) to provide the following CME activity for medical specialists. The EACCME® is an institution of the European Union of Medical Specialists (UEMS), www.uems.net

The CME conference is designated for a maximum of 11 (eleven) hours of European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

EACCME® credits are recognized by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME® credit to AMA PRA category 1 credit, please contact the AMA

Venue

This live educational conference will take place at:

Skolkovo Innovation Center
Bolshoi blv., 46, bld. 1
Moscow Oblast 143005 - Moscow, Russia
https://mimc.global

CME Provider

Med.E.A - Medical Education Academy
chloe.xilinas@medea.academy
Chairs & Faculty
Chairs

Carlo Alviggi
University Federico II
Naples, Italy

Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Robert Fischer
Fertility Center Hamburg
Hamburg, Germany

Peter Humaidan
Fertility Clinic, Skive Regional Hospital
Faculty of Health, Aarhus University
Aarhus, Denmark
Faculty

Carlo Alviggi
University Federico II
Naples, Italy

Vera Baukloh
Fertility Center Hamburg
Hamburg, Germany

Antonio Capalbo
Igenomix
Rome, Italy

Alessandro Conforti
University Federico II
Naples, Italy

Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Robert Fischer
Fertility Center Hamburg
Hamburg, Germany

Peter Humaidan
Fertility Clinic, Skive Regional Hospital Faculty of Health, Aarhus
University
Aarhus, Denmark

Igor V. Ivanov
Federal State Budgetary Institution “National Quality Institute”
Federal Health Care Supervisory Agency (Roszdravnadzor)
Moscow, Russia
Antonio La Marca  
University of Modena and Reggio Emilia and Clinica Eugin  
Modena, Italy

Marcos Meseguer  
IVI-RMA Global Valencia  
University of Valencia  
Valencia, Spain

Filippo M. Ubaldi  
G.E.N.E.R.A. Centre for Reproductive Medicine  
Rome, Italy

Irina Zorina  
Nova Clinic  
Center for reproductive medicine and genetics  
Moscow, Russia
Scientific Programme
Scientific Programme

Friday, 19 March 2021

08.00  Registration

09.00  Introduction
       R. Fischer, Germany

09.05  Welcome opening
       I. Zorina, Russia

Session I

Chair :  R. Fischer, Germany

09.15  L1  What is success in ART?
        F.M. Ubaldi, Italy

09.40  Questions
        F.M. Ubaldi, Italy

09.45  L2  The relevance of a QMS in ART clinic and
         laboratory
        V. Baukloh, Germany

10.10  Questions
        V. Baukloh, Germany

10.15  L3  Necessity of a QMS in ART for practical
         doctor
        I. V. Ivanov, Russia

10.35  Panel discussion

11.05  Coffee break
11.25  L4  How to define subgroups for COS and role of oocyte number  
A. La Marca, Italy

11.50  Questions  
A. La Marca, Italy

11.55  L5  The role of polymorphisms of gonadotrophins and their receptors in COS  
A. Conforti, Italy

12.20  Questions  
A. Conforti, Italy

12.25  L6  Characteristics of polymorphisms of gonadotrophin receptors in patients undergoing ART treatment  
I. Zorina, Russia

12:40  Panel discussion

13:10  Lunch

Session II

Chairs:  S.C. Esteves, Brazil - R. Fischer, Germany

14.30  L7  From poor response to low prognosis: the POSEIDON concept  
C. Alviggi, Italy

14.55  Questions  
C. Alviggi, Italy

15.00  L8  The ART Calculator and its role in the patient management  
S.C. Esteves, Brazil

15.25  Questions  
S.C. Esteves, Brazil
15.30    Panel discussion
16.00    End of the first day

Saturday, 20 March 2021

Chairs :    S.C. Esteves, Brazil - R. Fischer, Germany

09.00    L9    The management of POSEIDON group 1&2
C. Alviggi, Italy

09.25    Questions
C. Alviggi, Italy

09:30    L10    The management of POSEIDON group 3&4
P. Humaidan, Denmark

9.55    Questions
P. Humaidan, Denmark

10.00    L11    Ovulation - triggering strategies and the adequate luteal phase support
P. Humaidan, Denmark

10.25    Questions
P. Humaidan, Denmark

10.30    Panel discussion

11:00    Coffee break
Session III

Chairs: R. Fischer, Germany - P. Humaidan, Denmark

11.20 L12 The role of recent advancement in laboratory technology to improve ART outcome
M. Meseguer, Spain

11.45 Questions
M. Meseguer, Spain

11.50 L13 The role of pre-implantation testing for aneuploidy to improve selection. What are the limits?
A. Capalbo, Italy

12.15 Questions
A. Capalbo, Italy

12.20 Panel discussion

12.45 Lunch

Session IV

Chairs: C. Alviggi, Italy - R. Fischer, Germany

14.00 L14 The influence of the microbiota of the endometrium and the reproductive tract on the outcomes of ART
P. Humaidan, Denmark

14.25 Questions
P. Humaidan, Denmark
14.30  L15  The importance of the andrology and sperm evaluation aspects in ART outcome
S.C. Esteves, Brazil

14.55  Questions
S.C. Esteves, Brazil

15.00  L16  A quality management approach to COS-The Fischer Protocol
R. Fischer, Germany

15.25  Questions
R. Fischer, Germany

15.30  L17  Is the time ready for “freeze-all” strategy for all patients? What is the best frozen embryo transfer protocol?
F.M. Ubaldi, Italy

15.55  Questions
F.M. Ubaldi, Italy

16.00  Panel discussion

16.30  Concluding remarks and coffee
Faculty Disclosures
Faculty Disclosures

The faculty reported the following financial or product/device-related relationships and/or discussions of investigational or non-EMEA/FDA-approved (off-label) drug uses they or their spouse/life partner have with commercial interests related to the content of this educational activity:

Carlo Alviggi has declared receipt of honoraria or consultation fees: provision of services as consultant/advisor for Event Planet, EXCEMED and IBSA; and receipt of research grants from Merck. Participation in a speaker's bureau for Event Planet, EXCEMED, IBSA and Merck.

Vera Baukloh has declared receipt of honoraria or consultation fees from Merck.

Antonio Capalbo has declared receipt of honoraria or consultation fees from Merck.

Alessandro Conforti has declared receipt of honoraria or consultation fees from Merck Serono Spa.

Sandro C. Esteves has declared receipt of grants, contracts and honoraria or consultation fees from Merck. Member of Merck advisory board, board of directors or other similar group.

Robert Fischer has declared receipt of honoraria or consultation fees for lectures from Merck.

Peter Humaidan has declared receipt of grants, contracts and honoraria or consultation fees from Merck, Gedeon Richter, IBSA.
Antonio La Marca has declared receipt of grants, contracts and honoraria or consultation fees from Merck, MSD, Ferring, IBSA Teva, Beckman, Roche and participation in Merck, Ferring speaker's bureau.

Marcos Meseguer has declared benefit from a relationship with a commercial enterprise as speaker for Merck, Ferring, Vitrolife, MSD.

Filippo M. Ubaldi has declared receipt of grants and contracts Grant for Fertility Innovation, Merck; Forward 2016, Finox; Investigator Sponsored Trial ("IST"), Merck. Receipt of honoraria or consultation fees from Merck, Merck Serono, MSD, Ibsa, Excemed. Partnership: Genera Health Care srl.

Irina Zorina has declared no potential conflict of interest.

Igor V. Ivanov has provided no information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs as of 4 March 2020.
Carlo Alviggi earned his MD degree in 1994, from the Faculty of Medicine of the University of Naples “Federico II” in Naples, Italy; he specialized in obstetrics and gynaecology in 1998, and gained a PhD in 2001, from the same university.

During his career, he collaborated with: The Imperial College of London, in London, UK; the Laboratory of Immunology of the Italian National Research Council in Naples; and the Autoimmunity and Tolerance Laboratory of the University of California in Los Angeles, CA, USA. This network resulted in various publications, some of which concern new hypotheses on the pathogenesis of pelvic endometriosis. He is now an associate professor in reproductive medicine at the Fertility Unit of the University of Naples “Federico II”.

Professor Alviggi’s current research interests are the role of luteinizing hormone (LH) in folliculogenesis; the use of LH-containing drugs in patients undergoing ovarian controlled stimulation for IVF; the pathogenesis of pelvic endometriosis; oncofertility; reproductive endocrinology; and the genetics of human reproduction. He has participated in several national and international (phase 2 and 3) multicentric, prospective randomized trials.

Professor Alviggi has published extensively and has been invited to lecture at over 100 international meetings dealing with reproductive medicine and gynaecological endocrinology; he has also served as an ad hoc reviewer for international journals in these fields.
Vera Baukloh initially studied Zoology and Marine Science at the Christian-Albrechts-University of Kiel. In 1979 she joined the IVF group of Prof. L. Mettler at the Department of Gynaecology at the same university – which was one of only three such teams within Germany at that time. The first pregnancies of this group were achieved during her employment there.

In 1983 she changed to a private institute in Hamburg establishing the IVF laboratory for a successful programme of assisted reproduction there. Since 1998 she is the scientific laboratory director of the Fertility Center Hamburg, and also their Quality Management Representative.

Mrs. Baukloh has been a member of the executive board of the professional association of German reproductive embryologists (AGRBM) for several years, and is still actively involved in working committees of that association.
Antonio Capalbo
Igenomix
Rome, Italy

Antonio Capalbo received his Bachelor of Science degree in Biotechnology from University of Rome ‘La Sapienza’ and his Ph.D. magna cum laude in Human Genetics at the Catholic University of Sacred Heart of Rome in 2011.

Since 2008 Dr. Capalbo has been working as clinical embryologist at GENERA, Reproductive Medicine in Rome. Since then, his research has focused on preimplantation genetic testing and on the development of novel molecular biology techniques to improve pregnancy and take-home baby rates in ART.

He received several grants for innovative studies on these subjects. From 2012-2017 he was co-founder and Laboratory Director at GENETYX, largest PGT program in Italy. From 2017 he is working in the board of R&D directors at Igenomix and as Laboratory Director for Igenomix Italy.

He is currently senior deputy of the ESHRE SIG in Reproductive Genetics and member of the genomics-working group of the Italian society of human genetics. He has published more than 70 peer-reviewed papers and book chapters and is currently reviewer for many journals in the field of reproductive biology and genetics.
Alessandro Conforti received his MD in 2009 and in 2010 became Clinical Visitor of the In Vitro Fertilization (IVF) Department of Hammersmith Hospital, London, UK, directed by Dr Stuart Lavery.

During his specialization training from 2012 to 2013, he worked in the Minimally Invasive Therapy Unit & Endoscopy Training Centre at the Royal Free Hospital in London, UK, as Clinical Research Fellow, under the guidance of Consultant Gynaecologist Mr Adam Magos. During this period, he also worked as Clinical Research Fellow in the Fetal Medicine Unit at the Royal Free Hospital under the guidance of Head of Unit Mr Demetrios Economides.

Dr Conforti specialized in obstetrics and gynaecology in 2015. In 2017, he received his PhD from the University of Naples “Federico II” in Naples, Italy, with a thesis on neuroscience and reproductive medicine focused on the role of genetic variants of gonadotropins and their receptors in controlled ovarian stimulation.

Dr Conforti’s research interests include minimally invasive and reproductive gynaecological surgery, reproductive medicine, reproductive genetics, assisted reproductive technology, and oncofertility. He has served as an ad hoc reviewer for many international journals and is the author or co-author of several articles published in international peer-reviewed journals.
Sandro C. Esteves is Medical Director of Androfert – Andrology and Human Reproduction Clinic, a referral fertility centre for male reproduction in Campinas, Brazil. He received his MD from the University of Campinas (UNICAMP) in 1990, where he also undertook residency training in urology. He completed his training at the Cleveland Clinic’s Center for Reproductive Medicine in the USA from 1995 to 1996 and received his MSc in surgery from UNICAMP in 1998 and his PhD in urology from the Federal University of São Paulo, Brazil, in 2001.

Dr Esteves’ research and clinical interests include: male infertility and microsurgery; reproductive endocrinology; in vitro fertilization cleanroom technology; and quality management. He has 20 years’ experience directing a busy fertility centre providing a full range of diagnostic and treatment services.

His academic appointments include being a collaborating professor in the Department of Surgery at the University of Campinas, an honorary professor of reproductive endocrinology at the Faculty of Health, Aarhus University, Denmark, and research associate in the American Center for Reproductive Medicine at the Cleveland Clinic Foundation, USA.

Dr Esteves has authored over 300 scientific papers in peer-reviewed journals and over 100 chapters in textbooks; he is Associate Editor of Frontiers in Endocrinology – Reproduction and International Brazilian Journal of Urology. His current h-index is 50.
Robert Fischer is the founder and Medical Director of the Fertility Center Hamburg (FCH) in Hamburg, Germany. Dr Fischer trained in obstetrics and gynaecology at the University Hospital of Münster, Germany, from 1979 to 1982 and at the Queen’s Medical Centre, University of Nottingham, UK. In 1983, Dr Fischer pioneered the first German outpatient IVF unit in Hamburg and became its Medical Director. The unit moved to a new location in 1998, and its name was changed to the “Fertility Center Hamburg”.

In July 1998, the Fertility Center Hamburg was one of the first centres, both in Germany and worldwide, to introduce quality management, and it was certified according to the ISO 9001 and accredited for IVF laboratories (ISO 17025).

Dr Fischer’s main research interests are in the development of stimulation protocols, luteinizing hormone supplementation, and gonadotropin-releasing hormone agonist triggering, as well as further development of quality management systems in IVF centres. He is a founding member of the European Society of Human Reproduction and Embryology (ESHRE); a founding member of the POSEIDON (Patient Oriented Strategies Encompassing IndividualizeOocyte Number) group; Member of the Scientific Committee of Excellence in Medical Education (EXCEMED- formerly the Serono Symposia International Foundation) and Scientific Director of Med.E.A. (Medical Education Academy).
Igor V. Ivanov

Head of Federal State Budgetary Institution “National Quality Institute”
Federal Health Care Supervisory Agency (Roszdravnadzor)
Moscow, Russia

Igor V. Ivanov received his MD at 2000 from the Medical State University of Irkutsk, his PhD at 2004. From 2004 to 2006 he held the position of Deputy Director of the Regional Center for Psychological, Medical and Pedagogical Support, Director of the Center for the Prevention of Drug Addiction of Minors.

From 2007 to 2013 he held various positions in the administrative bodies of the Irkutsk Region, including the position of Minister for Physical Culture, Sports and Youth Policy. 2013–2014 – Vice-President of the non-profit partnership Baikal Media Group, then First Deputy Chairman – Chief of Staff of the Moscow Regional Branch of the All-Russian Public Organization Union of Russian Engineering Engineers.

Since March 2014, he has been General Director of Federal State Budgetary Institution "National Quality Institute" of the Federal Health Care Supervisory Agency.
Peter Humaidan is a specialist in reproductive endocrinology, professor at The Fertility Clinic Skive Regional Hospital, Aarhus University, Denmark and Honorary professor at Odense University, Denmark.

During his scientific work he has primarily focused on developing individualized treatment protocols for the infertile patient. His doctoral thesis (DMSc) explored the role of LH during the follicular and luteal phases in controlled ovarian stimulation. His main fields of interest are triggering of ovulation with GnRH agonist, use of GnRH antagonists, and OHSS prevention.

He is the founder of the international society “The Copenhagen GnRHa Triggering Workshop Group” and co-founder of the POSEIDON group which suggested a new stratification of the poor responder patient. Moreover, he is a past board member of the ESHRE SIG Endocrinology Group.

He authored and co-authored 187 + articles (H-index 44, Google Scholar) in international peer reviewed journals as well as the Danish guidelines for OHSS prevention and chapters in textbooks. Peter Humaidan has a wide international scientific network and is frequently invited as a speaker at international conferences.
Antonio La Marca is Professor of Obstetrics and Gynecology at the Mother-Infant Department of the University of Modena and Reggio Emilia, Italy and he is the Medical Director of Clinica Eugin, Modena, Italy. He graduated in Medicine and Surgery at the University of Siena in 1996, specializing in Obstetrics and Gynaecology at the same institution in 2001.

In 2006 he obtained a PhD, again at the University of Siena. He has been working at the Institute of Gynaecology and Obstetrics of the University Hospital of Modena since 2003. His clinical activity covers all the field of Reproductive Medicine and Surgery and has taken part in thousands of IVF cycles, laparoscopic and hysteroscopic surgical procedures.

Present scientific interests include: ovarian reserve and pharmacological manipulation of ovarian activity. His most impactful articles concerned the physiological significance of AMH and AFC, their measurement and clinical utility. Moreover, he has published a long list of original articles dealing with the prediction of ovarian reserve and response in IVF and the personalization of ovarian stimulation protocols.

He is author or coauthor of 128 articles published in peerreviewed journals and authored many 26 Antonio La Marca University of Modena and Reggio Emilia and Clinica Eugin Modena, Italy chapters in national and international textbooks. He has been an Invited speaker in more than 100 international congresses. He is involved in several phase three and four trials as Principal Investigator and is the recipient of many competitively assigned research funds. He is an active member of many national and international professional and scientific societies and a consultant for the Italian Ministry of Health for female fertility-related issues.
Marcos Meseguer received his Biological Sciences Degree from the University of Valencia in Spain. He performed a pre-doctoral fellowship in St Mary’s Hospital, Manchester University, United Kingdom. He received his Ph.D. Degree in Obstetrics and Gynecoloy and the European Doctor Degree in 2002 from the University of Valencia, Spain. He has also a master degree in Research Methods; Design and Statistics from Universidad Autónoma de Barcelona, Spain.

Actually is Scientific Supervisor and Senior Embriologist in the IVF unit of IVIRMA Valencia. Dr. Meseguer has received and nominated twice the prize paper of the American Society of Reproductive Medicine. Three times the Lalor Foundation International Award from the American Society of Andrology, three times the research award from the Spanish Society of Fertility and 5 times the research award from the Spanish Society of Embriology. He received the Robert Edwards prize paper award from RBM on line and was ASRM star award winner. The primary areas of his research are embryology and male infertility.

As Principal Investigator, his work has been funded through 20 projects sponsored by the Spanish Government, including 8 EUREKA, Horizon 2020 EUROSTAR projects (granted to high quality technological projects) supported by the European Community). He has one international patent. He has published over 150 scientific articles, with 5600 citations and h-index of 43, including the most cited paper in Human Reproduction during 2013. Additionally published 50 reviews or book chapters, edited the first time-lapse book and made more than 530 presentations at national and international congresses. He has been the Director of 13 Doctoral Thesis all qualified with “Cum Laude”, and actually is directing 6 PhD candidates. He is also Statistics Advisor of Equipo IVI and Associate Professor of the Master in Biotechnology from Valencia University.
Filippo Maria Ubaldi
G.E.N.E.R.A. Centre for Reproductive Medicine
Rome, Italy

Filippo Maria Ubaldi is Medical Doctor, Clinical Director at the GENERA Centres for Reproductive Medicine in Rome, Marostica, Umbertide and Naples, Italy. With academic degrees in Obstetrics and Gynaecology, Masters in Andrology and Reproductive Medicine, PhD at the Vrije Universiteit Brussel in Andrology and Reproductive Medicine, he is also intensely dedicated to educational, editorial and practitioner activities.

Co-author of 10 books on the topic of Reproductive Medicine, author and co-author of 146 scientific papers of which 131 are peer reviewed journals (PubMed 01/12/2018); author H-index is 43. Editor of the treaty on Reproductive Medicine ‘Medicina della Riproduzione Umana’ published in Italy in 2010.

Invited as speaker at 422 National and International congresses on the topic of Reproductive Medicine and has been Scientific Coordinator of 74 congresses and courses. Member of the ESHRE Executive Committee during 2005-2009, he has been Chairman of the 26th ESHRE Annual Meeting held in Rome in June 2010. In 2014 he received the Italian National Scientific License as full Professor in Obstetrics and Gynaecology and between 2014-2015 has been member of the technical advisory board established by the Ministry of Health on heterologous fertilization.
Irina Zorina graduated from Saratov State Medical Institute with a degree in General Medicine, did her clinical residency in obstetrics and gynecology. In 1996 Dr. Zorina got her Ph.D. by writing a dissertation on a topic “Pathogenesis and principles of treatment of female infertility in urogenital chlamydiosis.”

Specialized in the field of IVF at the Scientific Center for Obstetrics and Gynaecology, at the Sechenov Moscow Medical Academy. Diagnosis and treatment of infertility (including using the methods of ART), gynecological endocrinology. Over the years, 5400 IVF cycles have been performed.

Dr. Zorina has more than 40 scientific papers, has repeatedly spoken at Russian and international conferences on reproductive technologies. She was a member of the expert European Council for the Clinical Implementation of the Prolonged Form of Gonadotropins. She took part in the research of international pharmacological companies.

In 2016, at the 26th International Conference of the Russian Association of Human Reproduction, dedicated to the 30th anniversary of IVF in Russia, she was awarded for her contribution to the development of IVF in Russia. Dr. Zorina has more than 30 years of professional experience.
Educational Objectives
What is success in ART?

Filippo M. Ubaldi
G.E.N.E.R.A. Centre for Reproductive Medicine
Rome, Italy

Educational objectives:

• Define clinical success measures for IVF, in ART, etc.

• Introduce the concept of cumulative live birth rate (CLB) as an outcome measure

• Introduce the concept of time-to-pregnancy (TTP) as an outcome measure
The relevance of a QMS in ART clinic and laboratory

Vera Baukloh
Fertility Center Hamburg
Hamburg, Germany

Educational objectives:

• Recognize the reasons for introducing a Quality Management System (QMS) in a clinic and laboratory

• Understand what the Quality System Requirements in a clinic and laboratory

• Manage risk and safety in ART clinics and laboratories
Necessity of a QMS in ART for practical doctor

Igor Ivanov
Federal State Budgetary Institution “National Quality Institute”
Federal Health Care Supervisory Agency (Roszdravnadzor)
Moscow, Russia

Educational objectives:

• What are the benefits of QMS in ART for the clinic and staff

• Understand what the practical aspects of Quality System Requirements for physicians

• Identify risk management for routine practice

NOTES
How to define subgroups for COS and role of oocyte number

Educational objectives:

• Explain the rationale of personalized medicine in IVF

• Know the different biomarkers for identification of specific subgroups of infertile patients

• Describe new COS strategies for embryo/oocyte accumulation and illustrate applications in clinical practice

NOTES
The role of polymorphisms of gonadotrophins and their receptors in COS

Alessandro Conforti
University Federico II
Naples, Italy

Educational objectives:

- Review the meaning of specific genetic variants of the FSH system in female reproduction
- Review the meaning of genetic polymorphisms beyond the FSH and LH system in female reproduction
- Understand relative gonadotropin deficiency and its association with genetic variants

NOTES
Characteristics of polymorphisms of gonadotrophin receptors in patients undergoing ART treatment

Irina Zorina
Nova Clinic Center for reproductive medicine and genetics
Moscow, Russia

Educational objectives:

• The practical utility of genotype characterization in infertile women
• Understand the results of clinical studies
From poor response to low prognosis: The POSEIDON concept

Carlo Alviggi
University Federico II
Naples, Italy

Educational objectives:

• Explain the differences between poor response and low prognosis women

• Describe the POSEIDON classification of low prognosis women in ART

• Illustrate the application of the POSEIDON classification in clinical practice
The ART Calculator and its role in the Patient’s management

Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Educational objectives:

• Recognize the correlation between the number of oocytes retrieved and IVF success

• Understand the algorithm to identify the appropriate number of oocytes to obtain at least one euploid embryo

• Describe the utility of the novel “ART calculator” in management of IVF patients

NOTES
The management of POSEIDON group 1&2

Carlo Alviggi
University Federico II
Naples, Italy

Educational objectives:

• Clarify the definition of hypo-responders

• Clarify the difference between hypo-responders and poor responders

• Explore practical solutions for management and individualizing care of POSEIDON groups 1 and 2

NOTES
The management of POSEIDON group 3&4

Peter Humaidan
Fertility Clinic, Skive Regional Hospital
Faculty of Health, Aarhus University
Aarhus, Denmark

Educational objectives:

• Describe the clinical characteristics of women belonging to POSEIDON 3-4

• Describe the differences between women with expected and unexpected low prognosis according to the POSEIDON concept

• Discuss strategies and adjuvant therapies for management of patients in POSEIDON groups 3 and 4
Ovulation - triggering strategies and the adequate Luteal Phase support

Peter Humaidan
Fertility Clinic, Skive Regional Hospital
Faculty of Health, Aarhus University
Aarhus, Denmark

Educational objectives:

• Prevalence of impaired oocyte maturation among women undergoing ART
• Pathophysiology for oocyte maturation failure
• Therapeutic interventions: rationale for dual triggering and review of clinical data/case reports
The role of recent advancement in laboratory technology to improve ART outcome

Marcos Meseguer
IVI-RMA Global Valencia
Universidad de Valencia, Valencia, Spain

Educational objectives:

• Evaluate the role of time lapse technology in the IVF laboratory

• Describe the new non-invasive test for assessment of quality of embryo and oocytes

• Illustrate the recent advances in the IVF laboratory and their possible clinical applications

NOTES
The role of pre-implantation testing for aneuploidy to improve selection. What are the limits?

Antonio Capalbo
Igenomix
Rome, Italy

Educational objectives:

• Assess the indications for which preimplantation genetic testing for aneuploidies (PGT-a) may be considered
• Define patient selection criteria for PGT-a and understand the influence of mosaicism on the accuracy of PGT-a
• Describe the potential role of polar bodies in PGT-a
• Compare evidence and research needs regarding blastocyst vs. cleavage biopsy
The influence of the microbiota of the endometrium and the reproductive tract on the outcomes of ART

Peter Humaidan
Fertility Clinic, Skive Regional Hospital
Faculty of Health, Aarhus University, Aarhus, Denmark

Educational objectives:

• Describe the role of the microbiota in human reproduction
• Illustrate how the microbiota can influence embryo implantation and IVF outcomes
• Explain the possible implications in clinical practice

NOTES
The importance of the andrology and sperm evaluation aspects in ART outcome

Sandro C. Esteves
Androfert – Andrology and Human Reproduction Clinic
Campinas, Brazil

Educational objectives:

• Understand the diagnostic tools used for sperm assessment
• Be aware of the risks of sperm DNA damage
• Be familiar with new advanced technologies for evaluation of male factors
A quality management approach to COS-The Fischer Protocol

Robert Fischer
Fertility Center Hamburg
Hamburg, Germany

Educational objectives:

• Describe the novel “Fischer protocol”
• Know the experience and results of the Fisher protocol in clinical practice
• Discuss how the Fisher protocol can improve the quality of care

NOTES
Is the time ready for “freeze-all” strategy for all patients? What is the best frozen embryo transfer protocol?

Antonio La Marca
University of Modena and Reggio Emilia and Clinica Eugin Modena, Italy

Educational objectives:

• Know the advantages of embryo freezing in IVF
• Compare IVF outcomes of fresh vs. frozen embryo transfers
• Understand the long-term effects of cryopreserved embryo transfer in terms of obstetric and neonatal outcomes
Funding
Med.E.A. educational programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing reinvestigation uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Med.E.A. This independent programme is made possible thanks to an educational grant received from: Reproductive Medicine Agency (Nova Clinic).

And sponsors of the exhibition area:
Take a look at Me.E.A Website

Med.E.A. – Medical Education Academy – is a global medical education provider. It is dedicated to developing, implementing and evaluating medical education programs worldwide, offering support to health care professionals in their continuing professional development. Med.E.A. exists to drive healthcare forward through insightful education that can help deliver improved patient care.

At the heart of Med.E.A. is an independent and international pool of scientific experts, education experts, academics and leading healthcare professionals, each with a long-established background in medical education. Med.E.A. education programs cover the fields of andrology, cardiology, endocrinology and metabolism, immunology, neurology, reproductive medicine and ultrasound. Each focus area is led by a dedicated Med.E.A. Board of Experts comprising leading experts in the specific field.

www.medea.academy